Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharmaDive" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharmaDive for you to read. Along with our medical data and news we also list BioPharmaDive Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharmaDive Companies for you to search.
Pfizer, Roche and Novartis all have first-line drugs for ALK-positive lung cancer, putting pressure on Takeda to keep up in the increasingly competitive market.
One English and four Swiss manufacturing plants, as well as about 700 positions mainly located at the company's Basel campus, will be affected.
Results released at World Lung spell out the cancer immunotherapy's survival benefit, bolstering AstraZeneca's place in the earlier, locally advanced setting.
Roche owns the first successful Phase 3 study of an immunotherapy in the less-common lung cancer type. But others are closing in.
The pharma hopes the results will help Farxiga compete with Eli Lilly and Boehringer Ingelheim's rival Jardiance, which has carved out a leading position on the strength of its heart claims.
Asegua Therapeutics will sell authorized generics of Harvoni and Epclusa at an annual list price of $24,000 for the most common course of therapy.
More than two years after getting an OK to switch Prezista manufacturing from batch to continuous, the big pharma has no intention of backing away from the increasingly turned-to method of production.
Generics companies worry continuous manufacturing could become another tool for branded drugmakers to protect their products.
Contract services providers are receiving more interest from drugmakers keen on the technology's potential cost-savings and better efficiency.
On the whole, drugmakers remain wedded to traditional production styles that have served for decades. Some, however, are shifting to newer technology.
The CDER chief said the agency won't force companies that want to stay "in the 1940s" with traditional methods — as long as they meet FDA standards.
The micro-dystrophin program for Duchenne muscular dystrophy looks back on track roughly two months after regulators put it on pause.
Launch of FoundationOne Liquid will expand the Roche-owned firm's liquid biopsy offerings as demand for blood-based cancer testing grows.
Amarin's CEO called it "the single most significant advance in preventative cardiovascular drug therapy since the advent of statin therapy."
More nuanced, dynamic insights into patient experience can decrease the burden on patients by extrapolating from objective data sources and reducing the number of questionnaires being asked.
Doctors in the north of England have won the right to use Avastin to treat wet age-related macular degeneration.
Three biosimilar competitors to the blockbuster drug received backing from a key European committee last week.
The move comes weeks after the Atul Gawande-led venture tapped Jack Stoddard to be its chief operations officer.
Despite backing more than a dozen other drugs at its September meeting, the CHMP for a second time refused to support eteplirsen's marketing OK.
BARDA is concerned that repeat doses of naloxone would not be available in a large-scale terrorist attack involving weaponized opioids. So it's tapped Opiant to develop a long-acting opioid overdose agent.
Following reports of increased risks to Acadia's Parkinson's drug, an analysis by the regulator turned up no new safety findings.
ZS’s 2018 research finds that only 25% of doctors are comfortable letting AI help with diagnosis.
The Health Care Cost Institute found employer-sponsored insurance spending increased by 44% over the decade through 2016.
Damage from flooding brought by the storm was severe, but drugmaker production facilities appear to have avoided major disruptions to operations.
Though better known for the prostate cancer med, Astellas gets considerable revenue from bladder drugs and reported positive data Thursday for an experimental chronic kidney disease therapy.